Karyopharm Therapeutics Inc.

Phase 3 AI-extracted

selinexor

myelofibrosis

Resolved

105days ago

Phase 3 readout · Mar 24, 2026

What's at stake Phase 3 trial results for selinexor in myelofibrosis are due Mar 24, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 15h ago

“NEWTON, Mass . – March 24, 2026 – Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported topline results from its Phase 3 SENTRY trial, a randomized, double-b”

Add to calendar Post on X Reddit

Provenance